Preparation method of clostridium perfringens epsilon toxin-ferritin nanoparticle antigen
By constructing self-assembled nanoparticle antigens of soluble Epsilon toxin and Ferritin proteins, the problems of low yield and insufficient immune response of existing vaccines were solved, and a strong immune response and prevention effect was achieved.
Patent Information
- Application Number
- CN202410985783.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-23
AI Technical Summary
The existing Clostridium perfringen vaccine has problems such as low yield, high cost, local inflammatory response, nonspecific immune response and short-term immunity. The single protein has a small molecular weight and poor immunogenicity, making it difficult to effectively prevent diseases caused by epsilon toxin.
The soluble Epsilon toxin mutant and soluble Ferritin protein were constructed, and the nanoparticle antigen was self-assembled through SpyCatcher technology to form nanoparticle antigens, which were used to prepare the Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen.
It significantly promoted the production of IgG in mice against antigens, successfully induced cellular immune responses, which were stronger than single protein immune responses, and provided a more effective solution to prevent diseases.
Smart Images

Figure CN118931931A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of nanoparticle antigen preparation, and in particular to a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen. Background Art
[0002] Clostridium perfringens (C.perfringens) is a Gram-positive anaerobic bacterium that can produce endospores. It can survive normal cooking temperatures. If not eaten or refrigerated immediately, the surviving spores may germinate and produce toxins in cooked food. Clostridium perfringens is widely present in nature, not only causing serious losses to the economic development of animal husbandry, but also affecting human systemic diseases and gastrointestinal diseases. For example, in the human body, Clostridium perfringens can cause diseases such as gas gangrene, food poisoning, gastrointestinal disorders, liver and kidney damage. In animals, especially in pigs and poultry, Clostridium perfringens is the main pathogen of gangrenous dermatitis, enterotoxemia and necrotic enteritis.
[0003] The vaccines currently used in the market are mainly natural toxin vaccines prepared from the supernatant of inactivated Clostridium culture. This traditional vaccine based on inactivated whole-cell bacteria or heat-inactivated culture supernatant has played an important role in preventing Clostridium perfringens disease. However, such vaccines have problems such as low yield and high cost consumption, and vaccinated animals will have local inflammatory reactions, nonspecific and uncontrolled immune reactions, and short-term immunity; the main pathogenic factor of Clostridium perfringens is the exotoxin it secretes. The bacteria can secrete at least 18 exotoxins, mainly α, β, E and ι, and cause disease in humans or animals. Among them, Epsilon toxin (Etx, E) secreted by type B and type D Clostridium perfringens can cause enterotoxemia in sheep, goats and cattle. The toxin protein is composed of 311 amino acids in total length. Before activation, it is called a precursor toxin and has low toxicity; after activation by proteolytic enzymes, the toxicity is greatly enhanced after removing some amino acid fragments at the C-terminus and N-terminus. The toxin causes the efflux of K+ ions in cells, leading to cell apoptosis and sudden death of animals. Once absorbed, the activated Epsilon species enters multiple internal organs, including the brain. In the brain, the toxin acts on blood vessels, crosses the blood-brain barrier, produces perivascular edema, and affects several types of brain cells, including neurons, astrocytes, and oligodendrocytes. In addition to perivascular edema, edema also occurs in the blood vessel walls of the affected animals, which separates the astrocyte end feet from the affected blood vessels, causing hypoxia of the nervous system tissue.
[0004] In view of the defects of toxoid vaccines, many laboratories have tried to use expressed proteins to prepare subunit protein vaccines, but the current technology has two major defects: first, the expression product based on Escherichia coli has poor solubility and is easy to form inclusion bodies; second, the molecular weight of a single protein is small and the immunogenicity is poor, making it difficult to meet the requirements for vaccine production. Currently, most technologies are still in the laboratory research and development stage and have not yet been put into market application. Therefore, a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen is needed. Summary of the invention
[0005] The purpose of the present invention is to solve the problems of the prior art and to provide a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen.
[0006] In order to achieve the above object, the present invention adopts the following technical solutions:
[0007] The invention comprises the steps of constructing a soluble E toxin mutant and a soluble Ferritin protein respectively and purifying them, and then self-assembling the soluble E toxin mutant and the soluble Ferritin protein to form a nanoparticle antigen.
[0008] Furthermore, the construction method of the soluble E toxin mutant includes mutating the histidine at position 106 of the E toxin of Clostridium perfringens to proline, adding a Spy docking tag and a flexible connector to the carboxyl terminus of the polypeptide chain of the E toxin of Clostridium perfringens, connecting the fusion sequence to the cold expression vector pCold II, constructing the pCold II-E plasmid, and transforming it into the Escherichia coli expression strain BL21 to obtain a soluble E toxin mutant. The encoding nucleotide sequence of the soluble E toxin mutant is shown in SEQ ID NO: 1, and the amino acid sequence is shown in SEQ ID NO: 2. The soluble E toxin mutant was deposited by the General Microbiology Center of the China Microbiological Culture Collection Administration on May 13, 2024, and was classified and named Escherichia coli, with a deposit number of CGMCC No.30558.
[0009] Furthermore, the construction method of the soluble Ferritin protein includes fusing Ferritin with the Catcher tag gene and the 6His tag gene, cloning into the pET28a vector after codon optimization, constructing the pET28a-Ferritin plasmid, and transforming the plasmid into the Escherichia coli expression strain BL21 to obtain the ferritin-Catcher fusion gene. The encoding nucleotide sequence of the ferritin-Catcher fusion gene is SEQ ID NO: 3, and the amino acid sequence is shown in SEQ ID NO: 4. The soluble Ferritin protein was deposited by the General Microbiology Center of the China National Microbiological Culture Collection Administration on May 13, 2024, and was classified and named Escherichia coli, with a deposit number of CGMCC No.30559.
[0010] Furthermore, when the soluble E toxin mutant is purified, the pColdII-E protein is expressed in large quantities using 2×YT medium and purified using a Ni-NTA column.
[0011] Furthermore, when self-assembling the nanoparticle antigen, the soluble E toxin mutant and the soluble Ferritin protein are mixed by pipetting at a mass ratio of 1:1 and allowed to stand at 37° C. for 2 hours.
[0012] The preparation method of Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen is applied in the following aspects:
[0013] (1) Application in the preparation of anti-Clostridium perfringens specific antibodies;
[0014] (2) Use in the preparation of drugs for preventing diseases caused by Clostridium perfringens.
[0015] Compared with the prior art, the present invention has the following beneficial effects:
[0016] The present invention prepares Epsilon-Ferritin nanoparticles by docking soluble Epsilon toxin and Ferritin protein with the help of SpyCatcher technology. Antigen mouse immunization significantly promotes the production of IgG and successfully induces cellular immune response. The antigen immune response of Epsilon-Ferritin nanoparticles is stronger than that of single protein. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 A pCold-E plasmid map of a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention;
[0018] Figure 2This is an SDS-PAGE diagram of pCold II-E protein induced expression in a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention;
[0019] Wherein: Marker: protein molecular weight standard, 1 is the precipitate after pCold II-E induction, 2 is the supernatant after pCold II-E induction, 3 is the precipitate without pCold II-E induction, 4 is the supernatant without pCold II-E induction, 5 is the whole pCold II empty cell;
[0020] Figure 3 This is a pCold II-E protein purification diagram of a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention;
[0021] Wherein: Marker: protein molecular weight standard, 1 is the supernatant of pCold II-E before purification, 2 is the flow-through, 3 is the washing solution of 20mM imidazole, 4 is the washing solution of 40mM imidazole, 5-13 are the elution solutions of 250mM imidazole;
[0022] Figure 4 A pET28a-Ferritin protein particle map of a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention;
[0023] Figure 5 This is a pET28a-Ferritin protein induced SDS-PAGE diagram of a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention;
[0024] Among them: 1 is the pET28a empty supernatant, 2 is the pET28a empty precipitate, 3 is the pET28a-Ferritin uninduced supernatant, 4 is the pET28a-Ferritin uninduced precipitate, 5 is the pET28a-Ferritin induced supernatant, 6 is the pET28a-Ferritin induced precipitate;
[0025] Figure 6 This is a pET28a-Ferritin protein purification diagram for a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention;
[0026] Wherein: 1 is the supernatant of pET28a-Ferritin before purification, 2 is the flow-through solution, 3 is the washing solution of 20 mM imidazole, 4 is the washing solution of 40 mM imidazole, and 5-11 are the elution solutions of 250 mM imidazole;
[0027] Figure 7The SDS-PAGE electrophoresis diagram of the E-Ferritin fusion protein of the preparation method of Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention;
[0028] Among them: 1 is Ferritin protein, 2 is E protein, 3 is fusion protein
[0029] Figure 8 Transmission electron microscopy image of E-Ferritin fusion protein of a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention
[0030] Fig. 9 This is a graph showing the IgG detection results of a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention;
[0031] Fig.10 A schematic diagram of the ratio of serum IgG1 / IgG2a in a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention;
[0032] Fig.11 A schematic diagram of the level of IFN-γ produced by spleen cells stimulated by E toxin in a method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention;
[0033] Fig.12 This is an in vitro neutralization test diagram of the preparation method of Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen proposed in the present invention. DETAILED DESCRIPTION
[0034] The present invention is described in detail below in conjunction with the embodiments and accompanying drawings. However, it should be understood that the embodiments and drawings are only used to exemplify the present invention and do not constitute any limitation on the protection scope of the present invention.
[0035] The present invention is further demonstrated below in conjunction with specific embodiments:
[0036] Example 1 Expression and purification of soluble E toxin mutants
[0037] 1.1 Vector construction and expression identification
[0038] like Figure 1 and 2As shown, the histidine at position 106 of the E toxin of Clostridium perfringens was mutated to proline, a Spy docking tag and a flexible linker were added to the C-terminus, and the fusion sequence was connected to the cold expression vector pCold II to construct the pCold II-E plasmid, which was transformed into the Escherichia coli expression strain BL21 (DE3). The encoding nucleotide sequence was shown in SEQ ID NO: 1, and the amino acid sequence was shown in SEQ ID NO: 2. The clone was taken and shaken overnight in 2×YT medium. The next day, it was transferred to 10 mL 2×YT at 1%, and quickly shaken at 37°C and 220 rpm to OD600nm = 0.6-0.8. The temperature was lowered to 16°C, 20 μL IPTG was added, and the mixture was induced at 16°C and 180 rpm for 20 hours, and an empty load control was performed at the same time.
[0039] After induction, the bacterial solution was centrifuged at 8000 rpm for 5 min, and the precipitate was collected. 1 mL of PBS was added for resuspending, ultrasonically disrupted, and centrifuged at 12000 × g for 15 min at 4 °C. The lysate supernatant was collected and subjected to SDS-PAGE electrophoresis.
[0040] The soluble E toxin mutant Epsilon-Spy was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on May 13, 2024, with the deposit number: CGMCC No.30558, address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, classification number: Escherichia coli;
[0041] Results: The non-toxic and soluble E toxin mutant was successfully expressed.
[0042] 1.2 Large-scale expression and purification
[0043] like Figure 3 As shown, 500 mL of 2×YT medium was then used to express pCold II-E protein in large quantities and purified using a Ni-NTA column. After purification, SDS-PAGE was used to verify the purification results and the purified protein was collected.
[0044] Example 2 Expression and purification of soluble Ferritin protein
[0045] 2.1 Vector construction and initial expression
[0046] like Figure 4 and 5As shown, Ferritin was fused with Catcher tag gene and 6His tag gene, and cloned into pET28a vector after codon optimization. The constructed plasmid was named pET28a-Ferritin. The plasmid was transformed into E. coli expression strain BL21 (DE3), the encoding nucleotide sequence was shown in SEQ ID NO: 3, and the amino acid sequence was shown in SEQ ID NO: 4. The clone was picked and shaken overnight in 2×YT medium. The next day, it was transferred to 10mL 2×YT at 1%, and quickly shaken at 37°C and 220rpm to OD600 = 0.6-0.8. 20μL IPTG was added, induced at 28°C and 180rpm for 6h, and an empty load control was performed at the same time.
[0047] After induction, the bacterial solution was centrifuged at 8000 rpm for 5 min, and the precipitate was collected. 1 mL of PBS was added for resuspending, ultrasonically disrupted, and centrifuged at 12000 × g for 15 min at 4 °C. The lysate supernatant was collected and subjected to SDS-PAGE electrophoresis.
[0048] The soluble Ferritin protein was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on May 13, 2024, with the deposit number: CGMCC No. 30559, address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, classification number: Escherichia coli.
[0049] 2.2 Large-scale expression and purification
[0050] like Figure 6 As shown, 500 mL of 2×YT medium was then used to express pET28a-Ferritin protein in large quantities and purified using a Ni-NTA column. After purification, SDS-PAGE was used to verify the purification results and the purified protein was collected.
[0051] Example 3 Docking of ferritin and toxin protein
[0052] 3.1 BCA assay to detect the concentration of E protein and Ferritin protein
[0053] The purified E protein and Ferritin protein were detected using the BCA kit of Thermo Company, and BSA was used as the standard protein to draw a standard curve. The concentrations of E protein and ferritin were 1.476 mg / mL and 1.064 mg / mL, respectively.
[0054] 3.2 Docking of E protein and Ferritin protein
[0055] like Figure 7As shown, the E protein and the Ferritin protein were mixed by pipetting at a mass ratio of 1:1 and incubated at 37°C for 2 hours. After the incubation, SDS-PAGE electrophoresis was performed and a clear band was found at about 70 KDa, indicating that the E protein and the Ferritin protein were successfully docked.
[0056] 3.3 Electron microscopy images of docked proteins
[0057] like Figure 8 As shown, the recombinant fusion protein was analyzed by electron transmission microscopy, which showed a self-assembled nanoparticle structure with a diameter of 20-22 nm, which was larger than the diameter of the Ferritin protein (20 nm), indicating that the E protein was successfully assembled with the Ferritin protein to form Ferritin protein nanoparticles.
[0058] Example 4 Immunological Evaluation of Particle Antigens in Mice
[0059] 4.1 Immunization groups and immunization procedures
[0060] E and E-Ferritin recombinant proteins were mixed with equal volumes of aqueous solution and aqueous adjuvant, respectively, to prepare subunit vaccines, the E antigen content in the vaccine was 10 μg / mL, and the dose of E protein immunization in each group was ensured to be equal. Female Balb / c mice aged 6 weeks were randomly divided into 5 groups (n=5), namely PBS control group, E aqueous solution group, E-Ferritin aqueous solution group, E aqueous adjuvant group, and E-Ferritin aqueous adjuvant group. The mice were immunized with 100 μL of each group by subcutaneous injection in the back, and booster immunization was performed in the 4th week after immunization. Blood was collected from the sinus vein of the mice every 7 days before and after immunization, and the serum was separated and stored at -20°C.
[0061] 4.2 Detection of specific antibody levels against recombinant proteins in sera of immunized mice
[0062] 4.2.1 Detection of recombinant protein IgG levels in sera of immunized mice
[0063] like Fig. 9 As shown, in order to evaluate the changes in the level of E protein antibodies after mouse immunization, the E protein indirect Elisa method was used to detect the IgG antibody level of immunized mice. The results showed that the IgG level produced by the E-Ferritin-water adjuvant group was significantly higher than that of the E-water adjuvant group three weeks after the first immunization; the IgG level produced by the E-Ferritin-water solution group was significantly higher than that of the E-water solution group, indicating that ferritin has a good antigen presentation effect.
[0064] The antibody level of E-Ferritin docked with recombinant protein water adjuvant group was significantly higher than that of E single protein water adjuvant group, and the antibody level of E-Ferritin docked with recombinant protein without adjuvant group was also significantly higher than that of E single protein without adjuvant group, and the antibody level of E-Ferritin docked with recombinant protein without adjuvant group was almost reaching the antibody level of E protein water adjuvant, confirming that ferritin has the function of antigen presentation.
[0065] 4.2.2 Detection of IgG subtypes of recombinant protein in sera of immunized mice
[0066] like Fig.10 As shown in the figure, in mice, Th1 immune response will produce IgG2a antibodies, while Th2 immune response will produce IgG1 antibodies. The indirect ELISA method was used to detect the expression of IgG subtypes such as IgG1 and IgG2a in the serum of immunized mice. As shown in the figure, the immune levels of IgG1 and IgG2a subtypes in the fusion protein group with or without adjuvant were higher than those in the single protein group with or without adjuvant 21 days after immunization, and the IgG2a / IgG1 ratio of the fusion protein group was higher than that of the single protein group, indicating that the fusion protein triggered a stronger Th1 immune response in the body.
[0067] 4.2.3 Detection of IFN-γ
[0068] like Fig.11 As shown, spleen cells were taken from mice, and the spleen cells were stimulated with 5 μg of E protein for 48 hours, and the supernatant was diluted 4 times to detect the IFN-γ immune level. The results showed that the E-Ferritin water adjuvant group produced a very high IFN-γ cytokine compared with the E-water adjuvant (p<0.001), indicating that the E-Ferritin water adjuvant group caused the body to produce a cellular immune response.
[0069] 4.2.4 Determination of serum neutralizing antibody titer
[0070] 4.2.4.1 Minimum lethal dose concentration of CV-81 natural toxin
[0071] like Fig.12 As shown, the concentration of CV-81 natural toxin was determined to be 2.474 mg / mL by the BCA method. It was diluted 2-fold continuously and applied to MDCK cells to observe the number of cell pathological changes. The experiment showed that the minimum cell median lethal dose of CV-81 natural toxin was 0.015 μg / mL.
[0072] 4.2.4.2 Determination of in vitro neutralization test
[0073] The serum was diluted twice in succession, mixed with the minimum half lethal dose of CV-81 natural toxin at a volume ratio of 1:1, and incubated at 37°C for 1 hour. 100 μL of the mixed liquid was added to a 96-well plate with MDCK cells, and the cytopathic effect was observed for 24 hours. The results showed that the E water solution group diluted 512 times, the E-Ferritin water solution diluted 2048 times, the E water adjuvant group diluted 2048 times, and the E-Ferritin water adjuvant diluted 4096 times 21 days after the second immunization could neutralize the minimum cell half lethal dose of CV-81 natural toxin. In vitro neutralization tests showed that ferritin has a good immune presentation effect, which provides a new direction for the development of Clostridium perfringens vaccines.
[0074] The present invention successfully constructed highly soluble Epsilon toxin and Ferritin protein, docked the soluble Epsilon toxin and Ferritin protein with the help of SpyCatcher technology, and prepared Epsilon-Ferritin nanoparticles. Antigen immunization of mice significantly promoted the production of IgG and successfully induced cellular immune response. The antigen immune response of Epsilon-Ferritin nanoparticles was stronger than that of a single protein.
[0075] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. A method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen, characterized in that: After constructing and purifying the soluble E toxin mutant and the soluble Ferritin protein respectively, the soluble E toxin mutant and the soluble Ferritin protein are self-assembled to form nanoparticle antigens.
2. The method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen according to claim 1, characterized in that: The method for constructing the soluble E toxin mutant includes mutating the histidine at position 106 of the E toxin of Clostridium perfringens to proline, adding a Spy docking tag and a flexible connector to the carboxyl terminus of the polypeptide chain of the E toxin of Clostridium perfringens, connecting the fusion sequence to the cold expression vector pCold II, constructing the pCold II-E plasmid, and transforming it into the Escherichia coli expression strain BL21 to obtain a soluble E toxin mutant. The encoding nucleotide sequence of the soluble E toxin mutant is shown in SEQ ID NO: 1, and the amino acid sequence is shown in SEQ ID NO:
2. The soluble E toxin mutant was deposited by the General Microbiology Center of the China Microbiological Culture Collection Administration on May 13, 2024, and was classified and named Escherichia coli, with a deposit number of CGMCC No.30558.
3. The method for preparing the Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen according to claim 1, characterized in that: The construction method of the soluble Ferritin protein includes fusing Ferritin with a Catcher tag gene and a 6His tag gene, cloning into a pET28a vector after codon optimization, constructing a pET28a-Ferritin plasmid, and transforming the plasmid into the Escherichia coli expression strain BL21 to obtain a ferritin-Catcher fusion gene. The encoding nucleotide sequence of the ferritin-Catcher fusion gene is SEQ ID NO: 3, and the amino acid sequence is shown in SEQ ID NO:
4. The soluble Ferritin protein was deposited by the General Microbiology Center of the China National Microbiological Culture Collection Administration on May 13, 2024, and was classified and named Escherichia coli, with a deposit number of CGMCC No.30559.
4. The method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen according to claim 1, characterized in that: When the soluble E toxin mutant is purified, 2×YT medium is used to express pCold II-E protein in large quantities, and Ni-NTA column is used for purification.
5. The method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen according to claim 1, characterized in that: When self-assembling nanoparticle antigens, the soluble E toxin mutant and the soluble Ferritin protein are mixed by pipetting at a mass ratio of 1:1 and allowed to stand at 37° C. for 2 hours.
6. Application of the method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen according to any one of claims 1 to 5 in the following aspects: (1) Application in the preparation of anti-Clostridium perfringens specific antibodies; (2) Use in the preparation of drugs for preventing diseases caused by Clostridium perfringens.
Citation Information
Patent Citations
Modified transferrin fusion proteins
CN102268094A
Clostridium perfringens epsilon toxin recombinant subunit vaccine and production method thereof
CN107753940A
Nontoxic clostridium perfringens and clostridium septicum fusion protein vaccine and production method thereof
CN110051834A
Cited By
Clostridium perfringens alpha toxin-ferritin nanoparticle antigen as well as preparation method and application thereof
CN120098144A
